ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2369

Dermatomyositis Associated with Anti-Melanoma Differentiation-Associated Gene 5 Antibodies: A Longitudinal Analysis

Matthew Lewis1, Shufeng Li1, Lorinda Chung2 and David Fiorentino1, 1Dermatology, Stanford University, Stanford, CA, 2Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: calcinosis, dermatomyositis, interstitial lung disease and ulcers

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 10, 2015

Title: Muscle Biology, Myositis and Myopathies Poster II: Autoantibodies and Treatments in Inflammatory Myopathies

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Dermatomyositis (DM) patients
with anti-melanoma differentiation-associated gene 5 (MDA5) antibodies are at
increased risk of developing interstitial lung disease (ILD). The natural
history of ILD among this subset of DM patients is poorly characterized among
non-Asian populations. Skin disease studies in anti-MDA5 DM are largely
cross-sectional in nature. We sought to characterize the temporal trends in ILD
severity, cutaneous ulceration and calcinosis in anti-MDA5 DM patients.

Methods: We retrospectively
reviewed the charts of 25 anti-MDA5 DM patients seen between July 2004 and
September 2014.

Results: Of the 25 anti-MDA5 DM
patients seen, 23 patients were assessed for evidence of ILD (Table 1). 17
patients (74%) had evidence of ILD corroborated by both pulmonary function
tests (diffusion capacity (DLCO) less than 75% predicted or forced vital
capacity (FVC) less than 80% predicted) and high-resolution chest computed
tomography scans. The median time to ILD development was 5 months, (range 0-71
months), with 89% of patients developing ILD within 9 months from symptom
onset.

In the 12 patients with longitudinal data, we found a small, but
statistically significant increase in DLCO over time (Figure 1), 0.30% per
month (95% CI 0.02-0.58%, p=.036). All
12 patients with ILD received immunosuppressive therapy.

We found
a significant inverse relationship between DLCO and ulcer burden (p=0.006, Figure 2). The median times to onset of cutaneous
ulceration, ulcer healing and calcinosis were 6, 22 and 30 months,
respectively. Use of phosphodiesterase type 5 inhibitors, such as sildenafil,
was associated with ulcer healing in 3 patients with recalcitrant cutaneous
ulceration.

The proportionate mortality was significantly greater in anti-MDA5
DM patients (5/25=20%) vs non-MDA5 DM patients (7/148=4.7%)
(p=.016).

Conclusion: In this cohort, 17 of 25
(74%) of anti-MDA5 DM patients developed ILD, most (89%) within 9 months of
symptom onset. The ILD severity as measured by DLCO may improve over time with
treatment. Among anti-MDA5 DM patients with ILD, the severity of their skin ulceration
appears to correlate with ILD severity. The classic mucocutaneous feature of
anti-MDA5 DM, cutaneous ulceration, appears during the onset of ILD but usually
resolves and is replaced by calcinosis.



Disclosure: M. Lewis, None; S. Li, None; L. Chung, Gilead, 4; D. Fiorentino, None.

To cite this abstract in AMA style:

Lewis M, Li S, Chung L, Fiorentino D. Dermatomyositis Associated with Anti-Melanoma Differentiation-Associated Gene 5 Antibodies: A Longitudinal Analysis [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/dermatomyositis-associated-with-anti-melanoma-differentiation-associated-gene-5-antibodies-a-longitudinal-analysis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/dermatomyositis-associated-with-anti-melanoma-differentiation-associated-gene-5-antibodies-a-longitudinal-analysis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology